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A monoclonal antibody to the gpl20-CD4 complex has differential effects 
on HIV-induced syncytium formation and viral infectivity 
Krystyna Konopka,  1 Elizabeth Pretzer,  l Franco Celada z and Nejat  Diizgiine~ ~'3. 
1 Department of  Microbiology, University of  the Pacific, School of Dentistry, San Francisco, CA 94115, ~ Institute ..for 
Molecular Immunology, Hospital for Joint Diseases, New York University, New York, N Y  10003 and 3 Department of 
Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143, USA 
A murine monoclonal antibody (MAb F-91-55) raised 
against the complex of soluble CD4 and human 
immunodeficiency virus type 1 (HIV-1) gpl20 had 
previously been found to inhibit syncytium formation 
without inhibiting the interaction of CD4 with gpl20, 
and its binding site was localized within the first two 
domains (D 1/D2) of CD4. We investigated whether this 
antibody inhibited the infectivity of HIV-1 in the CD4 + 
T cell lines A3.01, Sup-T1 and H9. We also examined 
the effect of the antibody on syncytium formation 
between these cells and chronically infected H9 cells. 
Syncytium formation was found to depend critically on 
the incubation medium used. The effect of the MAb on 
HIV-1 infectivity was very limited with A3.01 and Sup- 
TI cells, although it inhibited syncytium formation 
between A3.01 or Sup-T1 and chronically infected H9 
cells. In contrast, the MAb inhibited significantly the 
infectivity of HIV-1 in H9 cells, but it also inhibited 
syncytium formation between H9 and chronically in- 
fected H9 cells to a greater extent than in the case of the 
other cell lines. Our results indicate that cellular systems 
used for syncytium assays differ in their susceptibility to 
inhibitory antibodies. In the A3.01 and Sup-T1 cell 
systems, the differences in the ability of the MAb to 
block viral entry or syncytium formation raise the 
possibility that the mechanisms of interaction of gp 120/ 
gp41 with cell membrane CD4 may be different in 
cell-cell and virus-cell membrane fusion. 
Introduction 
Human immunodeficiency virus type 1 (HIV-1) predomi- 
nantly utilizes the T cell surface antigen CD4 as a 
receptor for infection of susceptible cells (reviewed in 
Levy, 1993). Both the fusion of the viral and target CD4 + 
cell membranes and the fusion of HIV-infected cells with 
CD4 + cells is a pH-independent process, and is preceded 
by the binding of the viral envelope glycoprotein gpl20 
to CD4 (Lifson et al., 1986; Sodroski et al., 1986; 
Sinangil et al., 1988; Stein & Engleman, 1991; Levy, 
1993). The mechanism of this fusion reaction is an area 
of active investigation. Binding of gpl20 to CD4 is 
thought to induce conformational changes in both 
molecules (Moore et al., 1991 ; Sattentau & Moore, 1991 ; 
Eiden & Lifson, 1992) resulting in the interaction of the 
fusion domain at the N terminus of gp41 with the target 
cell membrane, leading to membrane fusion and the 
release of the viral nucleocapsid into the cytosol. 
* Author for correspondence [mail should be sent to address (1)]. 
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Although the mechanisms of virus-cell and cell--cell 
fusion are generally presumed to be similar, recent 
studies have indicated that there are significant differ- 
ences between them (Callebaut et al., 1994; Camerini & 
Seed, 1990; Kalter et al., 1991 ; Pantaleo et al., 1991 a, b; 
Sato et al., 1992). 
The high-affinity binding site for gpl20 on CD4 has 
been identified by mutagenesis, antibody-blocking and 
crystallographic techniques as comprising the comple- 
mentarity determining region 2 (CDR2)-like region and 
supporting fl-strands of the D 1 domain of CD4 (reviewed 
in Klasse et aI., 1993). Antibodies to this region block 
gpl20 and virus binding to CD4 + cells, HIV infectivity of 
CD4 + cells and HIV-1 mediated syncytium formation 
(McDougal et al., 1986; Sodroski et al., 1986; Peterson 
& Seed, 1988). In addition to acting as a receptor for 
virus binding, CD4 may also be involved in the 
subsequent membrane fusion step (Camerini & Seed, 
1990; Hasanuma et al., 1992; Poulin et al., 1991 ; Truneh 
et al., 1991). The CDR3-1ike region of CD4 (amino acids 
81-102) (Sattentau et al., 1989) is thought to be involved 
in HIV-mediated, CD4-dependent membrane fusion, 
independent of its role in binding to gpl20 (Choe & 
Sodroski, 1992; Lifson et al., 1988; Ohki et al., 1990; 
0001-2790 © 1995 SGM 
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Rausch et al., 1992; Camerini & Seed, 1990). Certain 
monoclonal antibodies (MAbs) directed against the non- 
gpl20 binding epitopes of CD4 were reported to block 
HIV infection and syncytium formation essentially 
without inhibiting CD4-gpl20 binding. These include a 
MAb (L71) to the CDR3-1oop (Truneh et  al., 1991), a 
MAb to the pre-CDR3-related region, amino acid 
residues 72-84 (Ohki et  al., 1992), a MAb (5A8) to the 
D2 domain (Burkly et  al., 1992; Moore et  al., 1992) and 
MAbs (Q425, Q428) to the D3 domain (Healey et al., 
1990). In contrast, some CD4 monoclonal antibodies 
have differing effects on HIV entry and cell-cell fusion. 
For example, an anti-CDR3 MAb, 13B8-2, inhibits both 
recombinant gpl20 binding to cell surface CD4 (or 
sCD4) and HIV-induced cell-cell fusion, but not the 
binding of viral particles to cell-surface CD4 or virus 
entry into CD4 + cells (Corbeau e t  al., 1993). MAbs (5D4, 
7C2) to the D3/D4 domains of CD4 inhibit HIV-1 
infection but have no effect on CD4-gpl20 binding and 
HIV-l-induced syncytium formation (Hasanuma et  al. ,  
1992). 
Another antibody raised against the complex of 
soluble CD4 and gpl20 blocks syncytium formation 
between CEM cells chronically infected with H1V-lm~ 
(or HIV-1Rv) and uninfected Molt 4 cells, without 
inhibiting the interaction of CD4 with gpl20 (Celada et  
al., 1990). The binding site of MAb F-91-55 (MAb 55) 
has been localized within the first two domains (D 1/D2) 
of CD4. The antibody exhibits greater binding to the 
gpl20 complex of CD4 than to CD4 itself, suggesting 
that it recognizes a gpl20-dependent conformational 
change in CD4. However, whether the antibody also 
inhibits viral infectivity has not been investigated (Celada 
et  al., 1990). Nevertheless, it has been assumed that MAb 
55 inhibits viral infectivity as well as syncytium formation 
(Moore et  at., 1992; Gershoni et at., 1993; Golding et  al., 
1993; Klasse et  al., 1993). In view of the differential 
effects of several antibodies on these two processes, we 
have examined the ability of MAb 55 to inhibit HIV-1 
infection of the CD4 + T cell lines A3.01, Sup-T1 and H9, 
as well as its effect on syncytium formation between these 
three cell lines and chronically HIV-1-infected H9 cells. 
M e t h o d s  
Compounds and antibodies. Murine monoclonal antibody (MAb F- 
91-55, referred to as MAb 55), was raised in mice immunized with the 
soluble CD4-gpl20 complex, as described by Celada et al. (1990), and 
was used either as a purified MAb or ascites fluid containing the MAb 
(ascites-55). Mouse immunoglobulin IgG1 was obtained from Becton- 
Dickinson; recombinant sCD4 was provided by Genentech. Phosphate- 
buffered saline containing 0.1 g/1 CaClo, 0.1 g/l MgC12.6H~O, 0.2 g/1 
KCI, 0.2 g/1KH~PO 4, 8.0g/1NaC1 and 2.16 g/1Na~HPO~.7H~O, 
designated PBS, was obtained from the UCSF Cell Culture Facility. 
Phosphate-buffered saline containing 10 mM-sodium/potassium phos- 
phate and 0-9 % NaC1, designated PBS Ca,Mg-free or PBS (CMF), was 
prepared from packets obtained from Zymed Laboratories and filter- 
sterilized. 
Cells and viruses. A3.01 cells were obtained from T. Folks (Centers 
for Disease Control, Atlanta, Georgia, USA). Sup-T1 cells from J. 
Hoxie and H9 cells from R. C. Gallo were provided by the AIDS 
Research and Reference Reagent Program (Division of AIDS, NIAID, 
NIH, Bethesda, Maryland, USA). H9/HTLV-IIIB cells were kindly 
provided by J. Mills (San Francisco General Hospital). H9 cells 
infected with HIV-IIIIB, at 4 ng viral p24 per 1 x 106 cells, m.o.i. = 
0-0002, were designated as H9/HIV-l~IIB and used 31 days post- 
infection. Viral p24 antigen was determined in cell-free supernatant by 
the antigen capture assay as described previously (Konopka et al., 
1990). All cell lines were maintained at 37 °C, under 5% CO 2 in 
Medium A consisting of RPMI 1640 medium (lrvine Scientific) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum 
(FBS), penicillin (50 units/ml), streptomycin (50/ag/ml) and L-glu- 
tamine (2 mM). The cells were split 1 : 6 and fresh medium was added 
every 3 to 4 days. HIV-1 LAy LA~ (formerly the LAV-BRU strain) (Wain- 
Hobson et al., 1991), initially provided by F. Barr6-Sinoussi (Pasteur 
Institute, Paris, France), was propagated in human lymphoblastoid 
leukemia (CEM) cells, and purified as described by Larsen et al. (1990) 
and stored at - 7 0  °C. The purified HIV-1 was propagated in A3.01 
cells and designated HIV-1 m~u. The supernatant of chronically infected 
H9/HTLV-I I IB  cells was used as a source of the HIV-1 strain HIV- 
lmR. The culture supernatants were harvested at times of peak p24 
production, filtered through Millipore filters of 0.22 gm pore diameter, 
and stored in 1 ml aliquots at - 8 0 ° C .  The reverse transcriptase 
activity of the virus stock solutions was 2-5x 10 s and 3.9x 
10 k c.p.m./ml for HIV-1Br~u and HIV-IIIIB, respectively, as detected by 
the method of Hoffman et al. (1985). The ELISA-reactive p24 protein 
yielded 2-6 gg/ml for H1V-I~R v and 0-3 ~tg/ml for HIV-lms. 
The tissue culture infectious dose, 50 % endpoint (TCIDs0), was 
determined as described by Johnson & Byington (1990). The infectious 
titre per 100 ng p24 antigen was 4.6 x 105 TCIDs0 (both on A3.01 and 
H9 cells) for HIV-1BR~, and 4"8 x 10 ~ TCIDs0 (on H9 cells) for HIV- 
Assays for CD4-dependent HIV-l-hlduced cell fusion. Syncytium 
formation was evaluated by inverted phase contrast microscopy at 
25 × magnification, as described by Lifson (1993). After 16-20 h of co- 
cultivation, syncytium formation had proceeded to its full extent and 
cell fusion was typically extensive enough to warrant a 3 + score. A 
score of 4+ was assigned to numerous large syncytia with a low 
number of viable cells and 5 + to numerous syncytia and no viable 
cells. Diluents alone served as a neutral control; sCD4, known to block 
HIV-l-induced syncytium formation, served as a positive control for 
inhibition of cell fusion. Since sCD4 inhibits a process different from 
that inhibited by MAb55, the sCD4 concentration dependence of the 
inhibition of syncytia was not determined in our studies. 
H I V  infection of  cells. Ceils (2 × 107/ml) were exposed to HIV-1 for 
2 h at 37 °C, washed three times to remove unbound virus, resuspended 
at 0.5 × 106 or 1 x 106 cells/ml in Medium A and cultured in 24-well 
culture plates (2 ml per well). Viral inocula were standardized by their 
p24 content and cultures were infected at a concentration of 2 or 4 ng 
p24 per 1 x 106 cells. Where indicated, cells were infected in the presence 
of MAb 55, then washed three times and cultivated further in the absence 
of antibody. The MAb 55 was present onh, during the initial exposure 
of cells to the virus, therefore, the level of p24 antigen determined in 
the culture medium several days later is a measure of the effect of the 
antibody on the initial infection by cell-free virus, i.e. virus-cell fusion. 
Since the cells were infected at a very low m.o.i, and subsequently 
washed~ the measured p24 values reflect de novo viral replication, and 
not any input virus. Control cells were treated similarly but not exposed 
to the virus. Every 2, 3 or 4 days, 1 ml of the supernatant was removed 
and fresh medium was added, p24 antigen in the harvested medium was 
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measured by ELISA (Konopka et al., 1990). Cell viability was assessed 
visually both with and without the use of trypan blue. The viability of 
the cells was determined before each experiment, and only cultures with 
> 98 % viability were used. In the infectivity experiments, viability was 
determined at times of p24 determination and ascertained to be 
comparable to controls. 
Detection of CD4. The presence of cell surface CD4 was examined by 
direct immunofluorescence assay, using fluorescein isothiocyanate 
(FITC)-conjugated Leu3 antibody (Becton-Dickinson), with FITC- 
conjugated mouse IgG as a control. The fluorescence distribution was 
analysed with a fluorescence-activated cell sorter (FACScan; Becton- 
Dickinson). 
Results 
Inhibition of HIV-l-induced syncytium formation by 
MAb 55 
We investigated the effect of  MAb 55 on syncytium 
formation between chronically infected H 9 / H T L V - I I I B  
or H9/HIV-1Hm cells and three uninfected CD4 + T cell 
lines, A3.01, Sup-T1 and H9. The relative efficacy of  
purified MAb and ascites-55 was compared in parallel 
experiments with Sup-T1 and A3.01 cells (Table 1). Both 
purified MAb and ascites-55 substantially inhibited 
syncytium formation, while no inhibitory effect was 
found for mouse IgG1 at 10 lag/ml. Complete inhibition 
was observed with purified MAb at 10 ~tg/ml and ascites 
at 1:200 or 1 : 100 dilution, with both cell lines. Sup-T1 
cells were less sensitive to the anti-fusion effect of  MAb 
than A3.01 cells; for example, at 1 lag M A b / m l  or 1:500 
dilution of  ascites-55, complete inhibition of syncytium 
formation was observed with A3.01 cells while some 
cell-cell fusion occurred with Sup-T1 cells (Table 1). 
To characterize the inhibitory effect of  MAb 55 on 
cell--cell fusion under the conditions used in the in- 
fectivity studies, we performed the assay in complete or 
serum-free medium and compared that with results 
obtained in PBS and PBS (CMF). H 9 / H T L V - I I I B  cells 
formed syncytia with Sup-T1 cells under all these 
conditions (Fig. 1). Ascites-55 blocked syncytium forma- 
tion to a much higher extent in serum-free than in 
complete medium. For  example, almost complete in- 
hibition was observed at a 1 : 100 dilution of ascites-55 in 
serum-free medium, while significant cell-cell fusion 
occurred in complete medium. Although syncytium 
formation was less efficient in PBS (CMF) (score 3 + )  
than in PBS (4 +) ,  the inhibitory activity of  ascites-55 
was comparable (Fig. 1). In contrast, syncytium forma- 
tion between H 9 / H T L V - I I I B  and H9 cells was very 
ineffÉcient (data not shown). However, the more recently 
developed H9/HIV-I~H ~ cells were capable of  forming 
syncytia with H9 cells at an efficiency comparable to that 
with Sup-T1 cells in complete medium (score 5 +) ,  and at 
a somewhat lower efficiency in serum-free medium (score 
3 + )  (Fig. 2). Syncytium formation between H9 and 
H 9 / H I V - I , ~  B cells was more sensitive to the inhibitory 
effect of  MAb than that between Sup-T1 and H 9 / H T L V -  
II IB cells (Figs 3, 4a  and 5a). Interestingly, fusion 
between H9 and H 9 / H I V - l m B  cells was also more 
sensitive to the assay conditions than was fusion between 
H 9 / H T L V - I I I B  and A3.01 or Sup-T1 cells. For  example, 
the efficiency of syncytium formation in the presence of 
PBS (score + )  or PBS (CMF) (score ± )  was very low 
(Fig. 2). 
The effect of MAb 55 on HIV-1 infectivity depends on 
the cell type 
We examined whether the inhibitory effect of  MAb 55 on 
HIV-mediated cell-cell fusion was also exerted on 
virus-cell fusion. A3.01, Sup-T1 or H9 cells were infected 
with HIV-1BR v or HIV-I~I m in the absence or presence of 
purified MAb 55 or ascites-55. FACS analysis indicated 
that 92 %, 98 % and 60 % of A3.01, Sup-T1 and H9 cells, 
respectively, were CD4-positive. The background-sub- 
tracted mean fluorescence was 100, 140 and 40 (arbitrary 
units), for A3.01, Sup-T1 and H9 cells, respectively. 
Surprisingly, in view of the dramatic inhibition of 
syncytia formation discussed above, the effect of  MAb 
on HIV-1 infectivity in A3.01 and Sup-T1 cells was very 
limited. The antibody at 0.1 lag/ml did not affect viral 
p24 production in A3.01 cells. When A3.01 cells were 
infected in the presence of 1 lag MAb/ml ,  the production 
Table 1. Syncytium formation in the presence of purified MAb F-91-55 and ascites 
containing MAb-55* 
Purified MAb (ixg/ml) Ascites-55 (dilution) 
Cell IgG 1 
type 0.1 1 10 1:2000 1:1000 1:500 1:200 1:100 (10 lag/ml) Control 
Sup-T1 + ± -- 2+ + _+ -- - 3+ 3+ 
A3.01 _+ - - + ± -- - - 3+ 3+ 
* Syncytia were scored 16-20 h after the addition of chronically infected H9/HTLV-IIIB cells to uninfected 
Sup-T1 or A3.01 cells. Appropriate dilutions of purified MAb 55 or ascites-55 were prepared in 200 lal PBS 
(CMF). MAb remained in the assay during the co-incubation period. 
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Sup-T1 cells 







Fig. I. Syncytium formation between Sup-Tl and H9/HTLV-IIIB cells under different conditions in the absence or presence of ascites- 
55 at a dilution of l : 500. 
of  p24 antigen in the culture supernatant was inhibited 
by 20% and 14.3%, on days 3 and 7 post-infection, 
respectively. At 10 ~tg/ml, the MAb reduced the in- 
fectivity of  the virus by only 16%. The MAb inhibited 
the infectivity of  the virus in Sup-T1 cells to a greater 
extent. The amount  of  p24 produced on day 3 was 
reduced by 20%, 31.1% and 44.4% at 0"1, 1.0 and 10 ~tg 
mAb/ml ,  respectively, and after 5 days the inhibition was 
43-5 %, 34-6 % and 56.2 %, respectively. The presence of  
mouse IgG1, at 10 gg/ml,  during initial infection did not  










Fig. 2. Syncytium formation between H9 and H9/HIV-1111B cells under different conditions in the absence or presence of ascites-55 at 
a dilution of  1 : 500. 
affect virus production appreciably when compared to 
untreated A3.01 or Sup-T1 cells (data not shown). 
We also determined virus production in A3.01 and 
Sup-T1 cells exposed to HIV-1B~ ~ in the presence of 
several dilutions of ascites-55. As with the purified MAb 
55, ascites-55 reduced the p24 production with Sup-T1 
cells to a greater extent than with A3.01 cells. For 
example, at a 1:100 dilution of ascites-55, 20% and 
674 K. Konopka and others 









Fig. 3. Syncytium formation between Sup-T1 and H9/HTLV-IIIB or H9 and H9/HIV-I m~ cells in complete medium A in the absence 
and presence of ascites-55, at dilutions of 1:500, 1:200 and 1 : 100. 
32"7 % inhibition of p24 production was observed with 
A3.01 and Sup-T1 cells after 7 days, respectively. 
Ascites-55 blocked syncytium formation between Sup- 
T1 and H9/HTLV-I I IB  cells to a much higher extent in 
serum-free than in complete medium (Fig. 1). To test 
whether the absence of serum can increase the inhibitory 
effect of  MAb on HIV-1 infectivity, p24 production was 
determined after the exposure of  Sup-T1 cells to either 
HIV-1B~ v or HIV-1HI B in serum-free medium. Under 
these conditions ascites-55 did not inhibit de novo 















Control 1:2000 1:1000 1:500 1:200 1:100 
Ascites F-91-55 
Fig, 4. Effect of ascites-55 on syncytium formation between Sup-T 1 and H9/HTLV-IIIB (a) and HIV-1 uiB replication in Sup-T1 cells 
(b). (a) Appropriate dilutions of ascites-55 in 200 gl O f serum-free medium were added to the wells containing uninfected Sup-T1 cells 
and infected H9/HTLV-IIIB cells were added subsequently. After 16 h of co-cultivation in the continuous presence or absence of 
antibodies, syncytium formation was scored (score 1 + = 1). (b) Sup-T1 cells were exposed to HIV-ImB at 2 ng p24 per l0 s cells (at 
an m.o.i, of 0.0001) in serum-free medium in the presence of antibody as described in Methods. p24 antigen was determined in cell 
culture supernatant on day 3 post-infection. Data represent the mean + standard deviation of p24 determinations in duplicate, in 
supernatants of two replicate wells (n = 4) or triplicate wells (control infections) (n = 6)~ 
infection with either HIV-lmB or HIV-1BR~j (Fig. 4b and 
data not shown). These results contrast sharply with the 
significant inhibition of  syncytium formation (Fig. 4a). 
Substantial differences were observed in the sensitivity 
of  Sup-T1 and H9 cells to the inhibitory effect of MAb 
on syncytium formation with infected cells (Fig. 3). To 
test whether the infectivity of  the virus might exhibit 
similar differences, we investigated the effect of  MAb 55 
on HIV-1 infection of H9 cells. When H9 cells were 
infected with HIV-1B~ v in the presence of  0.1 gg 
M A b / m l  in complete medium, virus production was 
inhibited by 60% and 36%, on days 7 and 10 post- 
infection, respectively. At 1 and 10 ~tg/ml, M A b  55 
reduced p24 production by 83.3% and 85"7%, re- 
spectively, on day 10 post-infection. A significant 
inhibitory effect was also observed when H9 cells were 
infected with the HIV-1B~u isolate at a concentration of 
13 ng p24 per 106 cells (m.o.i. = 0"06) in the presence of  
ascites-55 in serum-free medium. Ascites-55, diluted 
1 : 100, reduced p24 production by 73 % and 66.3 %, on 
days 4 and 7 post-infection, respectively. The M A b  
inhibited the infectivity of  HIV-lmB in H9 cells to an 
even greater extent (Fig. 5 b and data not shown). Virus 
production was reduced by 87%, 91% and 89%, on 
days 10, 14 and 17 post-infection, respectively, with a 
1:100 dilution of ascites-55. Thus, under the same 
conditions, ascites-55 inhibited significantly the infec- 
tivity of  HIV-lmB in H9 cells (Fig. 5b) without affecting 
its infectivity in Sup-T1 cells (Fig. 4b). 
Discussion 
Our results on HIV-l- induced syncytium formation 
demonstrate that (i) it is influenced by the composit ion of  
the medium; (ii) significant differences exist among 
various uninfected and infected T cells in supporting 
cell-cell fusion; and (iii) the different T cell lines differ in 
their sensitivity to the inhibitory effect of  MAb on HIV- 
induced syncytium formation. The molecular factors in 
the medium responsible for the different extents of  
syncytium formation are not known. The difference in 
the antibody sensitivity between the cell lines may be 

















Control 1:2000 1:1000 1:500 1:200 1:100 
Ascites F-91-55 
Fig. 5. Effect of ascites-55 on syncytium formation between H9 and H9/HIV-lmB (a) and HIV-1IIIB replication in H9 cells (b). (a) 
Appropriate dilutions of ascites-55 in 200 ~tl of serum-free medium were added to the wells containing uninfected H9 cells and infected 
H9/HIV-1H, B cells were added subsequently. After 16 h of co-cultivation in the continuous presence or absence of antibodies, 
syncytium formation was scored (score 1 + = 1). (b) H9 cells were exposed to HIV-I,~ B at 4 ng p24 per 106 cells (at an m.o.i, of 00002), 
in serum-free medium in the presence of antibody as described in Methods. p24 antigen was determined in cell culture supernatant on 
day 10 post-infection. Data represent the mean -4- standard deviation of p24 determinations in duplicate, in supernatants of two replicate 
wells (n = 4) or triplicate wells (control infections) (n = 6), 
related to the difference in the intrinsic susceptibility of  
the cells to HIV-induced fusion. For  example, H9 cells 
appear  to be less prone to extensive syncytium formation 
compared to Sup-T1 cells, and the inhibition of  cell-cell 
fusion by M A b  55 in this system is more pronounced. 
The lower syncytium-supporting ability of  H9 cells 
observed here may be due to the lower level of  CD4 
expression on the cells compared to Sup-T1 cells, the 
lower percentage of CD4 + cells in the cultures, and 
perhaps the lower fusogenic efficiency of H9 cells 
independent of  the CD4 level (Lu et al., 1992). Kaba t  et 
al. (1994) have found that the level of  CD4 present on the 
surface of  susceptible CD4 + cells is not the sole 
determinant of  virus entry or syncytium formation. The 
differences in syncytium formation observed under the 
different environmental conditions utilized in our studies 
are in agreement with the observation that Ca 2+ are 
required for HIV-induced cell fusion but not for binding 
of sCD4 to gpl20/gp41-expressing cells (Dimitrov et al., 
1993). Our observation that various T cells differ in their 
ability to support  HIV-induced syncytium formation 
under different conditions suggest that the 'fusogenic 
propert ies '  of  both uninfected CD4 + and infected cells 
influence syncytium formation. For  example, De Jong et 
al. (1992) reported that A3.01 cells do not support  
syncytium formation,  despite a high level of  viral 
replication, while in our studies A3.01 cells could easily 
form syncytia with chronically infected H9 cells. 
While our results on three different cell lines have 
confirmed previous observations that MAb 55 inhibits 
syncytium formation (Celada et al., 1990), they indicate 
that the antibody is not particularly inhibitory to HIV 
infectivity in Sup-T1 and A3.01 cells. This MAb is 
thought to prevent a post-binding event necessary for 
membrane fusion without inhibiting the interaction of  
CD4 with gpl20. One question raised by our findings is 
why virus-cell fusion should be less affected by the anti- 
body than cell-cell fusion in the A3.01 and Sup-T1 cell 
systems. I t  has been reported that a mutat ion (517A) in 
the N terminus of  HIV-1 gp41 markedly affects cyto- 
pathicity, with only minimal effects on virus replication 
(Kowalski et al., 1991). Similarly, virus entry is 
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disrupted less than syncytium formation by changes in 
HIV-1 gp41 residues 566 to 596 (Cao et  al., 1993). 
Mutations in the N terminus of HIV-2 gp41 which 
increase the charge and the polarity and/or decrease the 
hydrophobicity of the fusion domain severely reduce the 
capacity of the virus to induce syncytia, but only slightly 
affect virus infectivity (Steffy et  al., 1992). It is also 
possible that viral gp120/gp41 can interact more effect- 
ively than cellular gpl20/gp41 with accessory molecules 
in the cell membrane that may be involved in the 
membrane fusion reaction. Syncytium formation does 
not occur in LFA-1- CD4 + T lymphocytes despite 
efficient HIV infection (Pantaleo et  al., 1991a, b). In 
addition, HIV-1 isolates differ in their capacity to induce 
syncytia in vitro (Tersmette et  al., 1989). Clearly, assays 
for syncytia formation should not be used as sole 
indicators of HIV infection. 
Another question raised by our findings is why MAb 
55 inhibits HIV-1 infection in H9 cells more effectively 
than in A3.01 or Sup-T1 cells. One possibility is that 
the interaction of HIV-1 with H9 cell membranes leading 
to virus-cell membrane fusion and nucleocapsid delivery 
into the cytoplasm has more stringent molecular 
requirements than its interaction with Sup-T1 cells. 
Thus, MAb 55 can more readily interfere with the proper 
orientation or alignment of HIV-I envelope and cell 
surface molecules necessary for the membrane fusion 
reaction, subsequent to binding to CD4. Indeed, we have 
found that the extent of viral nucleocapsid delivery into 
H9 cells within 30 rain at 37 °C is 5'5-fold less than that 
into Sup-T1 cells, although the extent of membrane lipid 
mixing is comparable (L. Stamatatos, S. Nir & N. 
Dtizgiine~, unpublished data). This observation suggests 
that the membrane reorganization leading to complete 
membrane fusion (with nucleocapsid delivery) is less 
efficient in the case of H9 cells than Sup-Tl cells. Thus, 
the presence of the antibody interferes effectively with an 
already inefficient process in H9 cells, while it cannot 
interfere with an efficient fusion reaction in the case of 
Sup-T1 cells. Similarly, the cell type used markedly 
affects the anti-HIV activity of polyanionic compounds 
and glycosylation inhibitors (Schols et al., 1992). 
Recently, Gershoni et al. (1993) have described several 
MAbs against the CD4/gpl20 complex, some of which 
inhibit cell-~zell fusion to different degrees; however, 
their effect on HIV infection was not reported. Moore et 
al. (1992) have shown that pre incubat ion  of sCD4 with 
MAb 55 substantially reduces binding of sCD4 to HIV- 
lniB-infected H9 cells and, as a result, inhibits sCD4- 
induced gp120 shedding. In contrast, using recombinant 
proteins, Celada et al. (1990) have shown that MAb 55 
does not inhibit sCD4-gpl20 binding when all the 
components are co-incubated.  Thus, the results reported 
by Moore et  al. (1992) suggest that the formation of the 
sCD4-MAb complex is necessary for the inhibition of 
sCD4-gpl20 binding, and emphasize the importance of 
the experimental conditions in the interaction of these 
molecules. 
Investigations on the regions of CD4 other than the 
gp 120 binding site involved in HIV-1 envelope-mediated 
membrane fusion have provided contradictory data 
(Lifson et al., 1988; Camerini & Seed, 1990; Ohki et  al., 
1990; Rausch et al., 1992; Corbeau et  al., 1993; Broder 
& Berger, 1993). The role of the anti-CDR3 MAb 13B8- 
2, specific for sequences surrounding amino acid 87, is 
also controversial. According to Rey et al. (1991) and 
Corbeau et  al. (1993), MAb 13B8-2 blocks both the 
binding of gpl20 to sCD4 and HIV-induced syncytium 
formation, but has varying degrees of effect on virus 
binding to cell-surface CD4 and HIV-1 infectivity. Our 
observations that MAb 55 was more effective in blocking 
syncytium formation than HIV-1 infectivity are in 
general agreement with those of Rey et al. (1991) and 
Corbeau et  al. (1993) with MAb 13B8-2. Curiously, 
Dalgleish et al. (1984) presented data (in their Table 3) 
indicating that all the anti-CD4 MAbs they used 
inhibited both HIV-l-induced syncytium formation and 
pseudotype infection, while they noted in the text that 
pseudotype inhibition was not always achieved with 
some MAbs. 
Interestingly, MAbs 5D4 and 7C2 to the D3/D4 
domains of CD4 inhibit HIV-1 infection without 
inhibiting HIV-1 induced syncytium formation (Hasa- 
numa et  al., 1992), thus exerting the opposite differential 
effect compared to MAb 55. Similarly, the inhibition of 
infection without impairment of virus binding and 
syncytium formation was reported with a plant lectin, 
jacalin, which binds to the carbohydrates located on the 
D3/D4 domains of CD4 (Corbeau et al., 1994; Favero 
et  al., 1993). Thus, it becomes evident that although 
both virus-cell and cell-cell fusion require the specific 
interaction of gpl20/gp41 with CD4, there are other 
characteristics of CD4, aside from its gpl20 binding, 
which may play critical roles in post-binding events. 
Our studies have been performed with laboratory 
isolates of HIV-1. In view of the differences between such 
strains and primary isolates with respect to syncytium 
induction, tropism, CD4-dependence and susceptibility 
to inhibition by sCD4 (Daar et  al., 1990; Levy, 1993; 
Kabat et al., 1994), it will be useful in future studies to 
examine the effect of MAb 55 on infection of peripheral 
blood mononuclear cells by primary isolates and on 
syncytium formation in these cells. Finally, the ob- 
servation of Benkirane et  al. (1993) that the MAb 13B8- 
2 against the CDR3-1ike region of CD4 inhibits viral 
replication in previously HIV-infected CEM cells leads 
to the question of whether MAb 55 will have a similar 
effect in the same or other infected cell lines. 
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